SNIPER(ABL)-050

• UNSPSC Description:

  SNIPER(ABL)-050, conjugating Imatinib (ABL inhibitor) to MV-1 (IAP ligand) with a linker, induces the reduction of BCR-ABL protein[1].

• Target Antigen:

  Bcr-Abl; SNIPERs

• Type:

  Reference compound

• Related Pathways:

  PROTAC;Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/sniper-abl-050.html

• Solubility:

  10 mM in DMSO

• Smiles:

  CC1=CC=C(NC(C2=CC=C(CN3CCN(C(COCCOCCOCCNC([C@H](C(C4=CC=CC=C4)C5=CC=CC=C5)NC([C@H]6N(C([C@@H](NC([C@H](C)NC)=O)C7CCCCC7)=O)CCC6)=O)=O)=O)CC3)C=C2)=O)C=C1NC8=NC=CC(C9=CC=CN=C9)=N8

• Molecular Weight:

  1213.47

• References & Citations:

  [1]Shibata N, et al. Development of protein degradation inducers of oncogenic BCR-ABL protein by conjugation of ABL kinase inhibitors and IAP ligands. Cancer Sci. 2017 Aug;108(8):1657-1666.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported